These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2072463)

  • 21. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
    Nunberg JH; Schleif WA; Boots EJ; O'Brien JA; Quintero JC; Hoffman JM; Emini EA; Goldman ME
    J Virol; 1991 Sep; 65(9):4887-92. PubMed ID: 1714522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epitope specificity, antibody-dependent cellular cytotoxicity, and neutralizing activity of antibodies to human immunodeficiency virus type 1 in autoimmune MRL/lpr mice.
    Lombardi V; Placido R; Scarlatti G; Romiti ML; Mattei M; Mariani F; Poccia F; Rossi P; Colizzi V
    J Infect Dis; 1993 Jun; 167(6):1267-73. PubMed ID: 7684755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of murine monoclonal antibodies directed against the core proteins of human immunodeficiency virus types 1 and 2.
    Niedrig M; Hinkula J; Harthus HP; Bröker M; Hopp L; Pauli G; Wahren B
    J Virol; 1991 Aug; 65(8):4529-33. PubMed ID: 1712863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping of immunodominant epitopes of the HIV-1 and HIV-2 integrase proteins by recombinant proteins and synthetic peptides.
    Vinga-Martins C; Schneider T; Werno A; Roenspeck W; Pauli G; Mueller-Lantzsch N
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1301-10. PubMed ID: 1520543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
    Pantophlet R; Wilson IA; Burton DR
    J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA.
    Tiwari RP; Jain A; Khan Z; Kumar P; Bhrigu V; Bisen PS
    J Immunol Methods; 2013 Jan; 387(1-2):157-66. PubMed ID: 23098841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to the HIV-1 p17 protein cross-react with human superoxide dismutase-2.
    Kato T; Suzuki J; Daimon M; Sasaki H; Ishikawa K
    Biochem Biophys Res Commun; 1997 Jan; 230(1):184-7. PubMed ID: 9020042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides.
    Niedrig M; Hinkula J; Weigelt W; L'age-Stehr J; Pauli G; Rosen J; Wahren B
    J Virol; 1989 Aug; 63(8):3525-8. PubMed ID: 2473220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains.
    Goldstein G; Tribbick G; Manson K
    Vaccine; 2001 Feb; 19(13-14):1738-46. PubMed ID: 11166899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping.
    Barin F; Lahbabi Y; Buzelay L; Lejeune B; Baillou-Beaufils A; Denis F; Mathiot C; M'Boup S; Vithayasai V; Dietrich U; Goudeau A
    AIDS Res Hum Retroviruses; 1996 Sep; 12(13):1279-89. PubMed ID: 8870850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
    Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
    Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulation of human flap endonuclease 1 by human immunodeficiency virus type 1 integrase: possible role for flap endonuclease 1 in 5'-end processing of human immunodeficiency virus type 1 integration intermediates.
    Faust EA; Triller H
    J Biomed Sci; 2002; 9(3):273-87. PubMed ID: 12065902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunochemistry of the dominating antigenic region Ala582 to Cys604 in the transmembranous protein of simian and human immunodeficiency virus.
    Norrby E; Parks DE; Utter G; Houghten RA; Lerner RA
    J Immunol; 1989 Dec; 143(11):3602-8. PubMed ID: 2584709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fine mapping of an immunodominant region of the transmembrane protein of the human immunodeficiency virus (HIV-1).
    Döpel SH; Porstmann T; Henklein P; von Baehr R
    J Virol Methods; 1989 Aug; 25(2):167-77. PubMed ID: 2476460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigenic epitopes of NEF proteins from different HIV-1 strains as recognized by sera from patients with manifest and latent HIV infection.
    Gombert FO; Blecha W; Tähtinen M; Ranki A; Pfeifer S; Tröger W; Braun R; Müller-Lantzsch N; Jung G; Rübsamen-Waigmann H
    Virology; 1990 Jun; 176(2):458-66. PubMed ID: 1693246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
    Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS
    Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.